About Motiva® by Establishment Labs®

Establishment Labs® is a global medical technology company dedicated to improving women's health and wellness through the power of science, engineering, and technology.

Headquartered in Costa Rica with offices in Santa Barbara, CA and Austin, TX, the company offers a portfolio of Femtech solutions for breast aesthetics and reconstruction, including: **Motiva SmoothSilk® Round Implants, Motiva SmoothSilk Ergonomix® Implants, and the Motiva Flora® SmoothSilk® Tissue Expander.** Motiva Implants® are approved* for sale in more than 90 countries[1] worldwide, now including the United States.

*Motiva Implants® are not approved in the United States for reconstruction indication.

Motiva SmoothSilk® Round Implants

Motiva SmoothSilk Ergonomix® Implants

Motiva Flora® SmoothSilk® Tissue Expander

Establishment Labs® manufactures at two state of the art facilities in Costa Rica that are MDSAP-certified, LEED Gold certified and carbon neutral. Commercial facilities are located across 11 countries, including in Europe and South America, with distribution centers in Brazil and Belgium.

Please see HERE for downloadable company logos and visuals, including executive headshots.

Company Senior Leadership

Juan José Chacón-Quirós
Founder

Peter Caldini
CEO

Raj Denhoy
Chief Financial Officer

Roberto De Mezerville
Chief Technology Officer

Jeff Ehrhart
SVP & General Manager, North America

Rosalyn Cole D'Incelli
SVP, Global Clinical, Medical & U.S. Regulatory Affairs

Ross Mansbach
General Counsel & Chief Compliance Officer

Company Timeline

2004

Establishment Labs® was founded in Costa Rica, in response to an unmet need of safe and innovative Femtech solutions for breast health

2011

Motiva Implants® obtained CE-mark in Europe, the equivalent of U.S. FDA approval for the European Economic Area

July 2018

The company completed its Initial Public Offering (IPO)



August 2018

Establishment Labs® received FDA Investigational Device Exemption (IDE) approval to begin its Core Clinical Study for its Motiva SmoothSilk® Round and SmoothSilk Ergonomix® silicone gel-filled breast implants to support regulatory approval in the United States

October 2023

U.S. FDA clearance of Motiva Flora® SmoothSilk® Tissue Expander

September 2024

Motiva Implants® approved by the U.S. FDA*

*Motiva Implants® are not approved in the United States for reconstruction indication.

Establishment Labs® Financials*

The company trades on the NASDAQ stock exchange under the ticker symbol **ESTA** and has a market cap of around **$1.3 billion[2]**.

ESTA	$1.3B[2]
NASDAQ ticker symbol	estimated market cap

*Forward-Looking Statements

This advertising material contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). You can find many (but not all) of these statements by looking for words such as "approximates," "believes," "expects," "anticipates," "estimates," "intends," "plans," "intends to," "would," "will," "may" or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company's performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company's annual report on Form 10-K filed on March 4, 2024 and will be discussed in the company's quarterly report on Form 10-Q filed on August 7, 2024, which risks and uncertainties may be updated in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

1. Establishment Labs®, Post-Market Surveillance Preliminary Results Q1 2024. Internal Data on File.
2. Morningstar, Establishment Labs® Holdings Inc ESTA Stock Quote. Access November 8th, 2024.

IMPORTANT SAFETY INFORMATION

The Motiva SmoothSilk® Round and SmoothSilk Ergonomix® Silicone Gel Breast Implants are indicated for breast augmentation for women of at least 22 years old. Breast augmentation includes primary breast surgery to increase the breast size, as well as revision surgery to correct or improve the result of an original primary breast augmentation surgery (i.e., revision-augmentation). Breast Implant surgery is contraindicated in women with active infection anywhere in their bodies, with existing cancer or pre-cancer of their breast who have not received sufficient treatment for those conditions, or who are currently pregnant or nursing. Adequate studies have not been performed to confirm the safety of breast implant surgery in women with these conditions or under these circumstances; therefore, if you have any of the conditions or circumstances listed above, breast augmentation surgery with implants should not be performed at this time. Failure to take into consideration these contraindications may increase the risks involved with breast implant surgery and have the potential to cause harm. Patients should be advised that key complications have historically been associated with silicone gel breast surgery and implantation of silicone gel breast implants including, but not limited to, capsular contracture, implant removal, reoperation, infection, and rupture. Further, breast implants are not lifetime devices and patients should visit their healthcare professional, as recommended. For more detailed information about the benefits and risks of Motiva SmoothSilk® Round and SmoothSilk Ergonomix® Silicone Gel Breast Implants, please visit: www.motivausa.com or call Motiva at 1-800-924-5012.

The sale and distribution of this device is restricted to users and/or user facilities that provide information to patients about the risks and benefits of this device in the form and manner specified in the approved labeling provided by Establishment Labs® and Motiva® USA. Federal (USA) law restricts this device to sale by or on the order of a physician.

US-CORP-0005